Adverse Event Reporting
| VAERS ID | 1683492 |
|---|---|
| Gender | Male |
| Age | 77 |
| StateCode | TX |
| Pharmaceutical Company | PFIZER\BIONTECH |
| Lot Number | EN6198 |
| Number of vaccinations | 2 |
| Vaccinated | 2021-02-23 |
| Onset | 2021-08-17 |
| Condition | Hospitalized Died |
Symptoms
- Dyspnoea
- Cough
- Rhinorrhoea
- SARS-CoV-2 test positive
- Oxygen saturation decreased
- COVID-19
- Death
- Hypoxia
- General physical health deterioration
- Acute sinusitis
- Plasmapheresis
Current Illness
Preexisting Conditions
Anemia, Chronic Lymphocytic Leukemia, Diabetes, Hyperlipidemia, Hypertension, Myasthenia gravis, skin cancer
Other Medications
Albuterol nebs PRN, Apixaban 5 mg QD, atorvastatin 20 mg QD,azathioprine 100 mg BID, benzonatate 200 mg TID prn, Pulmicort flexhaler BID, carvedilol 6.25 mg BID, Dexamethasone 4 mg QD, ferrous sulfate 325 mg QD, finasteride 5 mg QD, Ibrut
Previous Vaccinations
Allergies
Sulfa Antibiotics
Laboratory Data
COVID-19 Positive on 8/11/2021 using PCR or equivalent
Write-up
Pfizer BioNTech COVID-19 Vaccine EUA: COVID-19 case resulting in Hospitalization / Death.
Patient received Pfizer Vaccines on 1/28/2021 and 2/23/2021.
Presented to physician office on 8/9/2021 for evaluation of dry non-productive cough, clear runny nose x3 days.
Was prescribed levofloxacin for acute sinusitis, benzonatate, albuterol nebs, and prednisone taper.
Patient called provider back on 8/11/2021 stating symptoms are still persistent and a COVID test was ordered w positive result.
on 8/12 the prednisone taper was discontinued and patient was prescribed dexamethasone 4 mg QD.
on 8/17/2021 patient presented to ED with shortness of breath and hypoxia.
Pulse ox on presentation was 70% on room air.
Patient was treated with dexamethasone, Remdesivir, ascorbic acid, zinc sulfate, and convalescent plasma.
Patient status deteriorated and was switched to comfort care on 9/4/2021, expired at 1335.